Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “AMINOCAPROIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,351 records · Page 75Linked to original sources
PubMed1983

Plasminogen-binding lipoprotein: isolation and characterization of a plasma very low density lipoprotein which co-chromatographs with plasminogen on lysine-sepharose.

By lysine-Sepharose chromatography, approximately 20% of normal plasma samples yield epsilon-aminocaproic acid (EACA) eluates which are opalescent, rather than clear, suggesting the presence of an additional, non-plasminogen component. This material has been isolated and characterized as a plasma lipoprotein of the very low density (VLDL) class on the basis of density ( less than 1.006 g/ml), size (greater than or equal to 5 X 10(7) daltons by gel filtration), electrophoretic mobility (pre-beta), chemical composition (mean cholesterol:triglyceride protein ratio, 1:3.4:1) and immunochemical evidence for apoproteins B, C, and E. Uniform particles, 100-200 Angstroms in diameter, were seen by electron microscopy. In contrast with VLDL in general, this lipoprotein co-chromatographed with plasminogen on lysine-Sepharose, where its binding was plasminogen-dependent, and from which it was eluted by EACA, but at lower concentrations than was plasminogen, suggesting a lysine-binding process. This plasminogen-binding lipoprotein (PBLP) was found in both male and female plasma samples, and increased post-prandially. Its properties suggest that it is a unique subclass of plasma VLDL. Although its isolation explains a laboratory phenomenon, and it exhibits interesting interactions with an important plasma zymogen, its function remains to be determined.

Carrier Proteins↗
PubMed1984

Cleavage of fibrinogen by human platelet calcium-activated protease.

In lysates of washed human platelets produced by sonication or by addition of nonionic detergent, fibrinogen (Mr 340,000) was rapidly degraded, under conditions favorable to activation of the endogenous calcium-activated protease (CAP), to a core derivative (Mr 280-290,000) composed of partially degraded A alpha chains (Mr 47,000, 46,000, and 34,000) and B beta chains (Mr 56,000), and apparently intact gamma chains (Mr 53-54,000). Extensive degradation occurred within one minute at 4 degrees C, ambient temperature or at 37 degrees C, and was inhibited by leupeptin, EDTA, EGTA, or N-Ethylmaleimide, but not by soybean trypsin inhibitor, hirudin, aprotonin, benzamidine, phenylmethylsulfonyl fluoride or epsilon-aminocaproic acid. Purified plasma fibrinogen exposed to lysates containing active protease was cleaved in an identical fashion. The cleavage pattern of A alpha chains produced by this platelet protease activity is different from that produced by plasmin in vitro or that found in fibrinogen catabolites in vivo, and is unlike that produced by any cellular fibrinolytic enzyme yet described. In view of this finding, as well as the striking differential inhibitory effect of the agents cited above, we conclude that the degradation of platelet fibrinogen observed in these studies is due to direct proteolysis by platelet CAP.

Blood Platelets↗
PubMed1986

Assay characteristics and fibrin affinity of plasminogen activators of the intrinsic fibrinolytic system.

Plasminogen activators (PA) in the euglobulin fraction of dextran sulfate activated plasma (DS-EF) were assayed on fibrin plates. Activity related to tissue plasminogen activator (t-PA) or urokinase (u-PA) was quantified by antiserum inhibition. The DS-EF contained 30% t-PA, 30% u-PA and 40-50% activity unrelated to t-PA or u-PA. The latter was completely inhibited by 1.7 mumol/1 C1-inhibitor (C1INH), the two former were less sensitive. Addition of flufenamate to the DS-EF (DS-EF/Fluf) from normal and two factor XII (F XII)-deficient plasmas increased their activities to the same high level. More than 50% of the activity was unrelated to t-PA or u-PA, 30-40% was u-PA and 5-10% t-PA related. After addition of fibrinogen to DS-EF/Fluf and clotting with thrombin, the remaining solution contained only about 30% of the total activity, including less than 10% u-PA. The epsilon-aminocaproic acid inhibition pattern obtained with the DS-EF was uniform, and thus different from the biphasic pattern obtained with the low fibrin affinity PA, two-chain urokinase. Thus, both the plasma u-PA and the major unidentified PA in plasma have affinity for fibrin.

Adult↗
PubMed1987

Studies on the anticoagulant action of Aspilia africana.

An anticoagulant activity was identified and isolated from the leaves of a West African plant, Aspilia africana by gel filtration on Sephadex G-100. The anticoagulant factor had an apparent molecular weight of approximately 60,000 d. Upon incubation with plasma, it prolonged the partial thromboplastin time, prothrombin time, thrombin and reptilase time. The factor decreased the fibrinogen content of plasma as well as the activity of coagulation factors V, VIII and IX but not factor VII, X or XI activities. After incubation with fibrinogen, the thrombin clotting time was prolonged and the quantity of clottable fibrinogen reduced. The action on fibrinogen was characterized by sequential lytic breakdown of the A-alpha-chain and B-beta-chain, the gamma-chain being lysed last, after prolonged incubation. Benzamidine, Epsilon aminocaproic acid or soybean trypsin inhibitor did not impede lysis.

Africa↗
PubMed1988

A model system for the in vivo determination of the thrombolytic effect of plasminogen activators.

An in vivo model system for measuring the thrombolytic efficiency of plasminogen activators was used. The formation of radiolabelled microthrombi was induced by infusion with I-125 labelled fibrinogen and thrombin. Reactive fibrinolysis was inhibited by administration of suboptimal levels of e-aminocaproic acid. The thrombolytic and subsequent fibrinolytic events were followed in the capillary bed of the lungs of anesthetized rats by external monitoring of the I-125 activity over the lung field. The model was successfully employed to demonstrate the thrombolytic effect of plasminogen activator produced by a transplanted spontaneous rat prostate adenocarcinoma cell line (PA III). The system proved to be reproducible with detection limits of 6000 I.U. using the PA-III cell line derived activator.

Animals↗
PubMed1989

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.

A case of hereditary angioedema (HAE) type I (inherited C1-inhibitor [C1 INH] deficiency) and a case of late-onset acquired C1 INH with angioedema is described. In both patients, long-term prophylaxis with C1 INH had become necessary because treatment with danazol and epsilon-aminocaproic acid was not effective or not tolerated. Consequently, both patients received a pasteurized concentrate of C1 INH continuously for a period of 1 year in a dosage that kept them free of symptoms. The patient with HAE was administered 500 units of C1 INH intravenously every 4 or 5 days, whereas the patient with acquired angioedema required 1000 units of C1 INH every 5 days. As a result of this long-term prophylaxis, both patients became free or nearly free from their episodes of cutaneous and internal edema. The low plasma levels of C1 INH, C4, and C2, rose. In the patient with acquired C1 INH deficiency, the swellings increasingly reappeared after 10 months, although the patient's antibody titer did not rise during treatment. No side effects were recorded during therapy. In particular, both patients remained HIV and hepatitis B antibody negative.

Angioedema↗
PubMed1984

Photoaffinity-labeled hapten-binding T-cell receptor on a suppressor T-cell hybridoma.

A T-cell hydridoma, 7C3-13-Ag6, which produces a (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific suppressor T-cell factor associated with an I-J determinant, was utilized to study the hapten-binding receptor of T-cells. This hybridoma had been shown to express NP-binding receptor molecules on the cell surface with heteroclitic fine specificity for a cross-reactive hapten, (4-hydroxy-5-iodo-3-nitrophenyl) acetyl (NIP). The stoichiometric analysis of the hapten binding by 7C3-13-Ag6 cells was performed by the measurement of direct binding of highly radioactive haptens to the cell surface. The affinity constant (Ka) of the receptor for N125IP-epsilon-aminocaproic acid (N125IP-cap), as calculated from a Hill plot, was 5.75 X 10(7) M-1 [Hill coefficient (a) = 0.86; expression of receptor sites per cell = approximately 1 X 10(3) on average]. The receptor molecule was specifically affinity labeled with photoreactive nitroaryl azide derivatives of N125IP (510-570 Ci/mmole). The specificity of photoaffinity labeling was demonstrated both by competitive inhibition of labeling with NIP- or NP-cap and by differential photoaffinity labeling based on the reversibility of hapten-receptor interaction. The gel electrophoretic analysis of the photoaffinity-labeled molecule indicated that the hapten-binding receptor of 7C3-13-Ag6 has a mol. wt of 28,000 +/- 3000 and an isoelectric point of 5.6-5.7. No immunoglobulin determinants were detected on the molecule. A comparative immunoprecipitation analysis of the membrane lysate of 7C3-13-Ag6 with monoclonal anti-I-J reagents identified a separate I-J molecule of 25,000 +/- 1000 mol. wt that is distinct from the photoaffinity-labeled hapten-binding molecule.

Affinity Labels↗
PubMed1986

Suppression of established IgE antibody responses with isologous anti-idiotypic antibodies in guinea pigs.

Guinea pigs of strains 2 and 13 can produce isologous anti-idiotypic (aIds) antibodies against anti-benzylpenicilloyl (anti-BPO) IgG, following immunization with affinity-purified anti-BPO antibodies of the same strain. The specificity of aId was determined by inhibition of binding of aId to Fab(t) in ELISA. The results showed that the reaction of strain 2 (anti-BPO)aId can be inhibited with syngeneic anti-BPO Fab(t) and to a smaller degree with anti-BPO Fab(t) of strain 13. On the other hand, strain 13 (anti-BPO)aId reacted exclusively with syngeneic anti-BPO Fab(t). In both cases, binding of aId to anti-BPO Fab(t) could not be inhibited with BPO-epsilon-aminocaproic acid, indicating that these aId are not directed against the antigen-combining site. The effect of isologous aId on both short- and long-time established IgE responses was studied in guinea pigs of strain 13. In both situations, administration of isologous aId resulted in suppression of the anti-BPO IgE antibody response. The suppressive effect was antigen-specific and lasted for several weeks: in the case of an early-response IgE remained suppressed despite additional booster injections of antigen. In contrast to the IgE response, the production of anti-BPO IgG antibodies was only slightly affected.

Animals↗
PubMed1985

Photoaffinity labeling of functionally different lysine-binding sites in human plasminogen and plasmin.

Photoaffinity labeling of human plasmin using 4-azidobenzoylglycyl-L-lysine inhibits clot lysis activity, while the activity toward the active-site titrant, p-nitrophenyl-p'-guanidinobenzoate, or alpha-casein are maintained. Photoaffinity labeling of native Glu-plasminogen with the same reagent causes incorporation of approximately 1.5 mol label per mol plasminogen. This labeled plasminogen can be activated to plasmin by either urokinase or streptokinase. The resulting plasmin has full clot lysis activity and can be subsequently photoaffinity labeled with a loss of clot lysis activity. The rate of activation of labeled plasminogen by urokinase is increased relative to that of native plasminogen. epsilon-Aminocaproic acid blocks incorporation of photoaffinity label into both plasminogen and plasmin, indicating that the labeling is specific to the lysine-binding sites. The labels are located in the kringle 1+2+3 fragment in either photoaffinity-labeled plasminogen or plasmin. These results indicate that the specific lysine-binding site blocked in plasmin acts in concert with the active-site in binding and using fibrin as a substrate. This clot lysis regulating site is not available for labeling in plasminogen, but is exposed or changed upon activation to plasmin. The different lysine-binding sites labeled in plasminogen may regulate the conformation of the molecule as evidence by an enhanced rate of activation to plasmin.

Affinity Labels↗
PubMed1990

Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue-type plasminogen activator.

A comparative kinetic analysis of the enzymatic activities of one-chain and two-chain tissue-type plasminogen activator (t-PA) demonstrates that two-chain t-PA catalyzes the hydrolysis of the peptide substrate D-Val-Leu-Arg-pNA about 4-fold more effectively than one-chain t-PA. The difference is accounted for almost entirely by a corresponding difference is the kcat values of the enzymes, whereas the Km values are similar. The amidolytic activity of two-chain t-PA is not enhanced by intact or partially plasmin-degraded fibrin. In contrast, the activity of one-chain t-PA is stimulated up to 3.7-fold by intact fibrin and up to 4.7-fold by plasmin-degraded fibrin (fibrin X-fragment). The stimulatory effects are realized via increases in the kcat values. It appears thus that in the presence of fibrin the intrinsically inferior catalytic properties of one-chain t-PA become similar to the properties of two-chain t-PA. The dependency of the activity of one-chain t-PA on the concentration of fibrin monomer is consistent with a single association site of both proteins and an association constant of Kass = 6.25 x 10(6) l/mol. Stimulation of one-chain t-PA by plasmin-degraded fibrin is more complex and appears to involve two different binding sites with association constants of Kass = 0.67 x 10(9) l/mol and Kass = 3.85 x 10(6) l/mol, respectively. The stimulatory effects of fibrin and partially plasmin-degraded fibrin on one-chain t-PA are suppressed by epsilon-aminocaproic acid and by a monoclonal antibody directed against the lysine binding site of t-PA. The latter findings support the notion that fibrin activation of one-chain t-PA is mediated by the lysine binding site on kringel domains of the enzyme.

Amino Acid Sequence↗
PubMed1989

Current status of antifibrinolytic drugs.

Antifibrinolytic drugs, in particular, epsilon-aminocaproic acid and tranexamic acid, have been used in the management of a wide range of both bleeding and non-haemorrhagic disorders. Recognition of their side-effects and complications, comparison of their efficacy with other forms of therapy and more critical evaluation of their value has reduced the range of their definitive indications to a limited number of relatively uncommon situations; these comprise primary hyperplasminaemia, menorrhagia in women in whom oestrogens are contraindicated or in those with von Willebrand's disease, severe traumatic hyphaema, dental extraction in haemophiliacs and hereditary angioedema in patients in whom treatment with anabolic steroids is contraindicated. In a few conditions the possible benefit of antifibrinolytic agents, alone or supplementary to other forms of therapy, is unresolved; these include upper gastrointestinal bleeding, recurrent epistaxis and abruptio placentae.

Antifibrinolytic Agents↗
PubMed1989

Hemostasis associated with abnormalities of fibrinolysis.

Hemostatic plugs consist of platelet aggregates and fibrin mesh containing blood cells and plasma components. Hemostatic efficiency depends on the rate of formation of hemostatic plugs as well as the structural integrity and stability of the formed hemostatic plugs. Fibrin elements are major constituents contributing to the structural integrity and stability, but they are subject to fibrinolytic activity occurring spontaneously after fibrin formation. Fibrinolysis is usually suppressed by endogenous inhibitors. Increase of a profibrinolytic component or deficiency of an inhibitor would result in an accelerated fibrinolysis, causing a premature lysis of hemostatic plugs before restoration of injured vessels, leading to a hemorrhagic tendency. Such a state can be seen typically in patients with congenital deficiency of alpha 2-plasmin inhibitor or a hereditary increase of plasminogen activator, and it is also seen in acquired situations such as amyloidosis, liver cirrhosis, disseminated intravascular coagulation (particularly in patients with acute promyelocytic leukemia) and thrombolytic therapy. The hemorrhagic tendency can be well controlled by an administration of an antifibrinolytic agent: epsilon-aminocaproic acid or tranexamic acid. In contrast to an accelerated fibrinolysis causing a hemorrhagic tendency, retarded fibrinolysis may predispose an individual to a thrombotic tendency. Retarded fibrinolysis may be due to either an increase in plasminogen activator inhibitors or decrease of plasminogen activators. Quantitative or qualitative deficiency of plasminogen may also lead to a thrombotic tendency.

Antifibrinolytic Agents↗
PubMed1992

Antitumor effect and toxicity of two new active-site-directed irreversible ornithine decarboxylase and extrahepatic arginase inhibitors.

The irreversible ornithine decarboxylase and extrahepatic arginase inhibitors (+)-S-2-amino-5-iodoacetamidopentanoic acid (2-AIPA) and (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) were evaluated. The LD50 tests were made in rats and mice using both compounds. Rats and mice were treated with either 2-AIPA or 2-AIHA i.p. for a period of 180 days. The treated animals showed a decrease of total serum proteins and increased ALT and AST levels. CK was also modified but inversely related to dose. Protection tests were carried out using L5178Y mouse lymphosarcoma. The mean survival time for each treated group was calculated and the percentage T/C was determined. For 2-AIPA it was 170 and for 2-AIHA it was 210 at 15 mg/kg.

Amino Acids↗
PubMed1984

Isolation of a 110 000 molecular weight protein in the purification of the nuclear chick intestinal 1,25-dihydroxyvitamin D-3 receptor.

A single protein band of molecular weight 110 000 has been obtained after sodium dodecyl sulfate polyacrylamide gel electrophoresis of purified 1,25-dihydroxyvitamin D-3 (1,25-(OH)2D-3) receptor from crude nuclear extracts of chick intestinal mucosa, prepared in the presence of the protease inhibitors phenylmethylsulfonyl fluoride and epsilon-aminocaproic acid. The nuclear extract was subjected to a six-step purification scheme, involving polymin P and ammonium sulfate fractionation, DNA-cellulose affinity chromatography, Sephacryl S-200 gel filtration, blue dextran-Sepharose and a final DNA-cellulose chromatographic step. The receptor was obtained in about 1% yield and was purified approx. 3700-fold from the nuclear extract, as assessed by specific activity. Single peaks were observed with 3H-1,25-(OH)2D-3-labeled crude nuclear extracts on Sephacryl S-200 gel filtration (Stokes' radius = 35.5 A) and sucrose density gradient centrifugation (3.5 S). Although the identity of the Mr 110 000 protein will remain inconclusive until methods for further characterization are available, it may represent evidence for a higher molecular weight form of the 1,25-(OH)2D-3 receptor than that observed previously.

Animals↗
PubMed1996

Labelling of haptenic drug with digoxigenin for competitive immunoassay: its application to lesopitron, a new anxiolytic agent.

A new labelling approach of haptenic drugs with digoxigenin for the development of competitive enzyme immunoassay (EIA) is reported. It consists of the covalent linking of the hapten to the preactivated digoxigenin derivative and revealing the immune complexes with anti-digoxigenin Fab fragments coupled to alkaline phosphatase. This approach has been applied to the development of an EIA for the pharmacokinetic study of lesopitron (E-4424), a new anxiolytic agent. The assay involves a solid-phase immobilization of IgG purified from polyclonal antiserum developed against the butylamino derivative of lesopitron covalently linked to bovine serum albumin. The tracer consists of the covalent linking of the same butylamino derivative to digoxigenin-3-O-methylcarbonyl-epsilon-aminocaproic acid N-hydroxysuccinimide ester. The calibration curve for E-4424 from 12.5 to 6400 pg per well displays an ED50 of 34.5 pg per well, a slope factor of 0.86 and a minimum detectable dose of 4.1 pg per well. The accuracy and the precision of the assay assessed at three different concentrations of E-4424 (500, 1000 and 2000 pg ml-1) give a recovery higher than 95% and intra- and inter-assay RSDs lower than 5 and 10%, respectively. The specificity of the assay was demonstrated by a good correlation of the samples analysed by both HPLC and EIA. A kinetic profile of E-4424 in rats following an oral dose of 50 mg kg-1 has also been established.

Animals↗
PubMed1991

Treatment of mammalian spinal cord injury with antioxidants.

After spinal cord injury, two groups of cats were treated with a combination of methylprednisolone sodium succinate (MP, 35 mg/kg) and epsilon-aminocaproic acid (EACA, 350 mg/kg), and guanabenz acetate (0.65 mg/kg). Guanabenz acetate was administered twice daily for 8 weeks. In the first group, the treatment significantly increased blood flow in the abdominal aorta. All cats treated with guanabenz acetate 3 hr after spinal cord contusion had return of micturition and none suffered complete paraplegia. Four animals had partial and the other four had complete motor recovery. A superoxide (O2-.) generating system, horseradish peroxidase, decreased [14C]gamma amino butyric acid uptake by mouse cortical slices by 33% but when superoxide dismutase was added to the medium, the uptake was reduced by only 9%. The nerve endings were also protected by superoxide dismutase from morphologic damage by O2-. as observed by electron microscopy. The agents used in these studies produce their ameliorating effects by virtue of their anti-inflammatory, antioxidant, and membrane stabilizing properties, and enhancing the regional microcirculation. In addition to having these properties, guanabenz acetate is also an alpha 2 adrenoceptor agonist.

Animals↗
PubMedDate not supplied

Interactions of the third component of human complement (C3) with tumour cells: evidence for presence of C3b acceptor sites and direct activation of C3 by tumour cells.

The interaction of C3 with different tumour cell lines was investigated. Our results indicated that nearly all the cell lines had C3b acceptors on their membranes. The binding of C3b was visualized by the detection of this protein on the cell surface with fluoresceinated anti-C3c serum. The involvement of proteases in the activation of C3 was demonstrated: complement-membrane fluorescence occurred in the presence of EDTA but was completely abolished with epsilon-aminocaproic acid. Experiments performed with purified C3 led to the conclusion that the protease activity might be the initial event for the activation of the alternative pathway by tumour cells.

Burkitt Lymphoma↗
PubMed1992

Decompensation in proteinase-inhibitor system and application of proteinase inhibitors in pemphigus and pemphigoid.

The goal of this study was to determine levels of serine proteinases and their inhibitors in serum and blister fluid of patients with pemphigus vulgaris (PV) and bullous pemphigoid (BP) in the course of treatment with prednisolone and proteinase inhibitors such as Contrycal and epsilon-aminocaproic acid. Assessment of the total proteolytic activity of serine proteinases (TPASP) and total antitryptic activity (TATA) is sera and blister fluids from 53 PV and 38 BP patients showed abnormalities in the proteinase and proteinase inhibitor levels in the acute stage of these bullous dermatoses. In PV, the level of TRASP was raised to 495 +/- 73 mU/ml (control 246 +/- 48 mU/ml; P < 0.001) in serum and to 849 +/- 96 mU/ml (control 189 +/- 34 mU/ml; P < 0.001) in blister fluid. In BP, the level of TRASP was raised to 472 +/- 101 mU/ml (P < 0.001) and 796 +/- 103 mU/ml (P < 0.001) in serum and blister fluid, respectively. In both dermatoses, the increase in serine proteinase activity developed against the background of decreased or unchanged antiproteolytic activity. TATA levels dropped to 16 +/- 5 inhibitory units (iU)/ml (control 26 +/- 5 iU/ml; P < 0.001) in PV serum and to 6 +/- 1 iU/ml (control 20 +/- 2 iU/ml: P < 0.001) in PV blister fluid. In BP, serum TATA levels were within normal values, whereas blister fluid TATA levels were significantly decreased (14 +/- 3 iU/ml; P < 0.1).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗